Latest Articles

Publication Date
Fertility preservation in endometriosis: current strategies and outcomes.

Endometriosis is a frequent chronic estrogen-dependent condition that can significantly impair fertility and reduce the quality of life in affected individuals. Women with endometriosis face a 30-50% risk of infertility. …

Published: Dec. 22, 2025, midnight
Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist.

Gonadotropin-releasing hormone (GnRH) antagonists inhibit estrogen synthesis and secretion, making them promising treatment options for estrogen-dependent diseases, such as endometriosis. This study developed a population pharmacokinetic/pharmacodynamic (PK/PD) model for merigolix, …

Published: Dec. 20, 2025, midnight
United States GnRH Agonists and Antagonists Drugs - openPR.com

United States GnRH Agonists and Antagonists Drugs openPR.com

Published: Dec. 3, 2025, 7:24 a.m.
The role of pharmacotherapy in the treatment of endometriosis: an update.

Endometriosis is a chronic inflammatory condition affecting ~10% of reproductive-age individuals and contributing significantly to infertility, pain, and reduced quality of life. Since our 2020 review, new pharmacologic strategies, updated …

Published: Dec. 2, 2025, midnight
Efficacy of Dienogest Versus GnRH Agonists After Endometriosis Surgery: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis compared the efficacy of dienogest (DNG) and gonadotropin-releasing hormone (GnRH) agonists in the management of endometriosis-related symptoms following surgical intervention, their related adverse effects, and …

Published: Nov. 22, 2025, midnight
Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy.

Relugolix, an oral GnRH receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol …

Published: Nov. 22, 2025, midnight
Risk factors for postoperative recurrence of deep infiltrating endometriosis during a 6- to 12-year follow-up.

This study aimed to identify risk and protective factors for postoperative recurrence of deep infiltrating endometriosis (DIE). We analyzed 320 patients undergoing laparoscopic excision with ≥ 6 years follow-up at …

Published: Oct. 28, 2025, midnight
Case Report: Long-term maintenance of GnRH-a combined with dienogest for thoracic endometriosis syndrome.

Thoracic endometriosis syndrome is a rare form of endometriosis in which endometrial tissue is thought to migrate to the lungs and, with the onset of menstruation, the ectopic foci bleed, …

Published: Oct. 27, 2025, midnight
Understanding Peritoneal Fluid Estrogen and Progesterone Concentrations Permits Individualization of Medical Treatment of Endometriosis-Associated Pain with Lower Doses, Especially in Adolescents Not Requiring Contraception.

Objectives: The aim of this study was to review the importance of peritoneal fluid steroid hormone concentrations to understand the mechanism of hormonal medical treatment of endometriosis-associated pain. Design: The …

Published: Oct. 12, 2025, midnight
Kuntai Capsule for the Treatment of Menopausal Symptoms Induced by GnRH-a Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Gonadotropin-releasing hormone agonists (GnRH-a) often induce menopausal symptoms, negatively affecting women's psychological, emotional, and physical health. Kuntai capsule is widely used in clinical practice to alleviate various menopausal symptoms. Exploring …

Published: Oct. 3, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!